Similar Clinical Characteristics Could be Present in Both VHL-Mutant and Wild Type Clear Cell RCC


Patients with VHL-mutant and wild type clear cell renal cell carcinoma may have comparable clinical characteristics, although other genetic alterations may be at play.

Similar clinical characteristics may occur in those with VHL-mutant and wild type clear cell renal cell carcinoma (ccRCC), which may be attributed to other genetic alterations, according to study findings that were presented at the 2021 European Society of Medical Oncology Congress

Findings from this study demonstrate that this may have the potential to impact clinical trial treatment selection.

“Further study of ccRCC based on VHL mutations status in the clinical trial setting appears warranted,” Gennady Bratslavsky, MD, of SUNY Upstate University Hospital in Syracuse, New York, and colleagues wrote in the poster.

Researchers performed comprehensive genetic profiling in 948 patients with clinically advanced ccRCC to assess all classes of genomic alternation. Of these patients, 75% had VHL-mutated disease (median age, 62 years; 71% men) and 25% had VHL wild type ccRCC (median age, 63 years; 71% men).

Some of the significant differences in currently “untargetable” genomic alterations included higher TERT genomic alterations in patients with VHL wild type ccRCC (P = .007) and higher frequencies of SETD2 in those with VHL mutated ccRCC (P = .04). Patients with VHL mutated or VHL wild type ccRCC had similar frequencies of genomic alterations that could potentially be targeted except for MTAP deletions; these deletions were observed more frequently in patients with VHL wild type ccRCC (P = .03).

Researchers also assessed patients with genomic alterations associated with immune checkpoint inhibitor efficacy. In these patients, PBRM1 genomic alterations were significantly more frequent in those with VHL wild type disease compared with VHL mutated disease (P < .0001). Patients with ccRCC had low tumor mutational burden levels, with 1% to 2% of patients having levels above 10 mut/Mb.

Patients with VHL mutated ccRCC and those with VHL wild type disease often had low positive PD-L1 expression (1%-49% tumor cell staining). In addition, both groups rarely had high positive staining (≥ 50% tumor cell staining).


Bratslavsky G, Necchi A, Grivas P, et al. Comprehensive Genomic Profiling of VHL Mutated and VHL Wild Type Clear Cell Renal Cell Carcinoma. Presented at 2021 ESMO Congress; September 16-21, 2021; Virtual. Abstract 690P

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content